bpc-157 scam FDA panel votes to ease restrictions on an unregulated peptide An FDA panel votes today

EGRIFTA WR (NDC 62064-381-04) is available in a package comprised of two boxes, containing 4 (four) 11.6 mg single-patient-use vials of EGRIFTA WR in the Medication Box and 1 (one) multiple-dose 30 mL bottles of Bacteriostatic Water for Injection, USP, diluent with a 28-day supply of disposable syringes, needles and alcohol swabs in the Injection Box

Side effects are uncommon and typically limited to mild injection site reactions

Personalized Regimens Your health and goals are unique, and so is your peptide plan

Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel diseases (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system